Refine
Year of publication
Language
- English (115)
Has Fulltext
- yes (115)
Is part of the Bibliography
- no (115)
Keywords
- e +-e − Experiments (8)
- Particle and Resonance Production (4)
- Spectroscopy (4)
- Exotics (3)
- Quarkonium (3)
- BESIII (2)
- Charm Physics (2)
- BPTF (1)
- Born cross section measurement (1)
- Branching fraction (1)
- CP violation (1)
- Cell Biology (1)
- Charmed mesons (1)
- Charmonium (-like) (1)
- Chemorefractory advanced gastric cancer (1)
- Dark photon (1)
- Dark sector (1)
- Ebola virus (1)
- Electroweak Interaction (1)
- Electroweak interaction (1)
- Extended donor criteria (1)
- FOLFIRI (1)
- FOS: Physical sciences (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Flavor symmetries (1)
- HSP (hereditary spastic paraplegia) (1)
- Hadronic decays (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Invisible decays (1)
- KLHL11 (1)
- Lepton colliders (1)
- Microbiology, Virology & Host Pathogen Interaction (1)
- N471D strumpellin knock-in mice (1)
- NURF (1)
- Organ allocation (1)
- Pancreas transplantation (1)
- Polarization (1)
- QCD (1)
- Rejection (1)
- SARS-CoV-2 (1)
- SPG8 (1)
- Sunitinib (1)
- Systems & Computational Biology (1)
- Tyrosine kinase inhibitor (1)
- VEGF (1)
- WASH complex subunit 5 (1)
- Y states (1)
- animal experiments (1)
- charmonium-like states (1)
- electron-positron collision (1)
- epitope mapping (1)
- hadron spectroscopy (1)
- helicity amplitude analysis (1)
- human sera (1)
- intranasal administration (1)
- mice (1)
- monoclonal antibody (1)
- neutralizing antibodies (1)
- neutralizing antibody (1)
- recombinant vesicular stomatitis virus‐Zaire ebolavirus (1)
- strumpellin (1)
- tetraquark (1)
- topical administration (1)
- transduction (1)
- virus (1)
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.
Aims: We investigated N471D WASH complex subunit strumpellin (Washc5) knock-in and Washc5 knock-out mice as models for hereditary spastic paraplegia type 8 (SPG8). Methods: We generated heterozygous and homozygous N471D Washc5 knock-in mice and subjected them to a comprehensive clinical, morphological and laboratory parameter screen, and gait analyses. Brain tissue was used for proteomic analysis. Furthermore, we generated heterozygous Washc5 knock-out mice. WASH complex subunit strumpellin expression was determined by qPCR and immunoblotting. Results: Homozygous N471D Washc5 knock-in mice showed mild dilated cardiomyopathy, decreased acoustic startle reactivity, thinner eye lenses, increased alkaline phosphatase and potassium levels and increased white blood cell counts. Gait analyses revealed multiple aberrations indicative of locomotor instability. Similarly, the clinical chemistry, haematology and gait parameters of heterozygous mice also deviated from the values expected for healthy animals, albeit to a lesser extent. Proteomic analysis of brain tissue depicted consistent upregulation of BPTF and downregulation of KLHL11 in heterozygous and homozygous knock-in mice. WASHC5-related protein interaction partners and complexes showed no change in abundancies. Heterozygous Washc5 knock-out mice showing normal WASHC5 levels could not be bred to homozygosity. Conclusions: While biallelic ablation of Washc5 was prenatally lethal, expression of N471D mutated WASHC5 led to several mild clinical and laboratory parameter abnormalities, but not to a typical SPG8 phenotype. The consistent upregulation of BPTF and downregulation of KLHL11 suggest mechanistic links between the expression of N471D mutated WASHC5 and the roles of both proteins in neurodegeneration and protein quality control, respectively.
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20
The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti‐EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Here, the analysis of serum samples from an EBOV vaccine trial with the recombinant vesicular stomatitis virus‐Zaire ebolavirus (rVSV‐ZEBOV) and an Ebola virus disease survivor, using high‐density peptide arrays, is presented. In this proof‐of‐principle study, distinct IgG and IgM antibodies binding to different epitopes of EBOV GP is detected: By mapping the whole GP as overlapping peptide fragments, new epitopes and confirmed epitopes from the literature are found. Furthermore, the highly selective binding epitope of a neutralizing monoclonal anti‐EBOV GP antibody could be validated. This shows that peptide arrays can be a valuable tool to study the humoral immune response to vaccines in patients and to support Ebola vaccine development.
In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell transplantation. However, literature about the influence of NK-DLI on recipient's immune system is scarce. Here we present concomitant results of a noninvasive in vivo monitoring approach of recipient's peripheral blood (PB) cells after transfer of either unstimulated (NK-DLI(unstim)) or IL-2 (1000 U/ml, 9–14 days) activated NK cells (NK-DLI(IL-2 stim)) along with their ex vivo secreted cytokine/chemokines. We performed phenotypical and functional characterizations of the NK-DLIs, detailed flow cytometric analyses of various PB cells and comprehensive cytokine/chemokine arrays before and after NK-DLI. Patients of both groups were comparable with regard to remission status, immune reconstitution, donor chimerism, KIR mismatching, stem cell and NK-DLI dose. Only after NK-DLI(IL-2 stim) was a rapid, almost complete loss of CD56(bright)CD16(dim/−) immune regulatory and CD56(dim)CD16(+) cytotoxic NK cells, monocytes, dendritic cells and eosinophils from PB circulation seen 10 min after infusion, while neutrophils significantly increased. The reduction of NK cells was due to both, a decrease in patients' own CD69(−) NCR(low)CD62L(+) NK cells as well as to a diminishing of the transferred cells from the NK-DLI(IL-2 stim) with the CD56(bright)CD16(+/−)CD69(+)NCR(high)CD62L(−) phenotype. All cell counts recovered within the next 24 h. Transfer of NK-DLI(IL-2 stim) translated into significantly increased levels of various cytokines/chemokines (i.e. IFN-γ, IL-6, MIP-1β) in patients' PB. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and/or extravasation. In contrast, NK-DLI(unstim) did not cause any of the observed effects. In conclusion, we assume that the adoptive transfer of NK-DLI(IL-2 stim) under the influence of ex vivo and in vivo secreted cytokines/chemokines may promote NK cell trafficking and therefore might enhance efficacy of immunotherapy.
Background: Simultaneous pancreas kidney transplantation (SPK), pancreas transplantation alone (PTA) or pancreas transplantation after kidney (PAK) are the only curative treatment options for patients with type 1 (juvenile) diabetes mellitus with or without impaired renal function. Unfortunately, transplant waiting lists for this indication are increasing because the current organ acceptability criteria are restrictive; morbidity and mortality significantly increase with time on the waitlist. Currently, only pancreas organs from donors younger than 50 years of age and with a body mass index (BMI) less than 30 are allocated for transplantation in the Eurotransplant (ET) area. To address this issue we designed a study to increase the available donor pool for these patients.
Methods/Design: This study is a prospective, multicenter (20 German centers), single blinded, non-randomized, two armed trial comparing outcome after SPK, PTA or PAK between organs with the currently allowed donor criteria versus selected organs from donors with extended criteria. Extended donor criteria are defined as organs procured from donors with a BMI of 30 to 34 or a donor age between 50 and 60 years. Immunosuppression is generally standardized using induction therapy with Myfortic, tacrolimus and low dose steroids. In principle, all patients on the waitlist for primary SPK, PTA or PAK are eligible for the clinical trial when they consent to possibly receiving an extended donor criteria organ. Patients receiving an organ meeting the current standard criteria for pancreas allocation (control arm) are compared to those receiving extended criteria organ (study arm); patients are blinded for a follow-up period of one year. The combined primary endpoint is survival of the pancreas allograft and pancreas allograft function after three months, as an early relevant outcome parameter for pancreas transplantation.
Discussion: The EXPAND Study has been initiated to investigate the hypothesis that locally allocated extended criteria organs can be transplanted with similar results compared to the currently allowed standard ET organ allocation. If our study shows a favorable comparison to standard organ allocation criteria, the morbidity and mortality for patients waiting for transplantation could be reduced in the future.
Trial registered at: NCT01384006
Background: As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response.
Methods: This double-blind, placebo-controlled, multicenter, phase II clinical trial was conducted to evaluate the efficacy, safety and tolerability of SUN as an adjunct to second and third-line FOLFIRI (NCT01020630). Patients were randomized to receive 6-week cycles including FOLFIRI plus sodium folinate (Na-FOLFIRI) once every two weeks and SUN or placebo (PL) continuously for four weeks followed by a 2-week rest period. The primary study endpoint was progression-free survival (PFS). Preplanned serum analyses of VEGF-A, VEGF-D, VEGFR2 and SDF-1α were performed retrospectively.
Results: Overall, 91 patients were randomized, 45 in each group (one patient withdrew). The main grade ≥3 AEs were neutropenia and leucopenia, observed in 56 %/20 % and 27 %/16 % for FOLFIRI + SUN/FOLFIRI + PL, respectively. Median PFS was similar, 3.5 vs. 3.3 months (hazard ratio (HR) 1.11, 95 % CI 0.70–1.74, P = 0.66) for FOLFIRI + SUN vs. FOLFIRI + PL, respectively. For FOLFIRI + SUN, a trend towards longer median overall survival (OS) compared with placebo was observed (10.4 vs. 8.9 months, HR 0.82, 95 % CI 0.50–1.34, one-sided P = 0.21). In subgroup serum analyses, significant changes in VEGF-A (P = 0.017), VEGFR2 (P = 0.012) and VEGF-D (P < 0.001) serum levels were observed.
Conclusions: Although sunitinib combined with FOLFIRI did not improve PFS and response in chemotherapy-resistant gastric cancer, a trend towards better OS was observed. Further biomarker-driven studies with other anti-angiogenic RTK inhibitors are warranted.
Trial registration: This study was registered prospectively in the NCT Clinical Trials Registry (ClinicalTrials.gov) under NCT01020630 on November 23, 2009 after approval by the leading ethics committee of the Medical Association of Rhineland-Palatinate, Mainz, in coordination with the participating ethics committees (see Additional file 2) on September 16, 2009.
Filoviruses infect a wide range of cell types with the exception of lymphocytes. The intracellular proteins cathepsin B and L, two-pore channel 1 and 2, and bona fide receptor Niemann–Pick Disease C1 (NPC1) are essential for the endosomal phase of cell entry. However, earlier steps of filoviral infection remain poorly characterized. Numerous plasma membrane proteins have been implicated in attachment but it is still unclear which ones are sufficient for productive entry. To define a minimal set of host factors required for filoviral glycoprotein-driven cell entry, we screened twelve cell lines and identified the nonlymphocytic cell line SH-SY5Y to be specifically resistant to filovirus infection. Heterokaryons of SH-SY5Y cells fused to susceptible cells were susceptible to filoviruses, indicating that SH-SY5Y cells do not express a restriction factor but lack an enabling factor critical for filovirus entry. However, all tested cell lines expressed functional intracellular factors. Global gene expression profiling of known cell surface entry factors and protein expression levels of analyzed attachment factors did not reveal any correlation between susceptibility and expression of a specific host factor. Using binding assays with recombinant filovirus glycoprotein, we identified cell attachment as the step impaired in filovirus entry in SH-SY5Y cells. Individual overexpression of attachment factors T-cell immunoglobulin and mucin domain 1 (TIM-1), Axl, Mer, or dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) rendered SH-SY5Y cells susceptible to filovirus glycoprotein-driven transduction. Our study reveals that a lack of attachment factors limits filovirus entry and provides direct experimental support for a model of filoviral cell attachment where host factor usage at the cell surface is highly promiscuous.
Acute kidney injury is associated with mortality in COVID-19 patients. However, host cell changes underlying infection of renal cells with SARS-CoV-2 remain unknown and prevent understanding of the molecular mechanisms that may contribute to renal pathology. Here, we carried out quantitative translatome and whole-cell proteomics analyses of primary renal proximal and distal tubular epithelial cells derived from human donors infected with SARS-CoV-2 or MERS-CoV to disseminate virus and cell type–specific changes over time. Our findings revealed shared pathways modified upon infection with both viruses, as well as SARS-CoV-2-specific host cell modulation driving key changes in innate immune activation and cellular protein quality control. Notably, MERS-CoV infection–induced specific changes in mitochondrial biology that were not observed in response to SARS-CoV-2 infection. Furthermore, we identified extensive modulation in pathways associated with kidney failure that changed in a virus- and cell type–specific manner. In summary, we provide an overview of the effects of SARS-CoV-2 or MERS-CoV infection on primary renal epithelial cells revealing key pathways that may be essential for viral replication.
The Born cross sections of the e+e− → D*+D*− and e+e− → D*+D− processes are measured using e+e− collision data collected with the BESIII experiment at center-of-mass energies from 4.085 to 4.600 GeV, corresponding to an integrated luminosity of 15.7 fb−1. The results are consistent with and more precise than the previous measurements by the Belle, Babar and CLEO collaborations. The measurements are essential for understanding the nature of vector charmonium and charmonium-like states.
We report the first measurements of the absolute branching fractions of D0 → K0 Lϕ, D0 → K0Lη, D0 → K0Lω, and D0 → K0Lη0, by analyzing 2.93 fb−1 of eþe− collision data taken at a center-of-mass energy of 3.773 GeV with the BESIII detector. Taking the world averages of the branching fractions of D0 → K0Sϕ, D0 → K0Sη, D0 → K0Sω, and D0 → K0Sη0, the K0S − K0L asymmetries RðD0; XÞ in these decay modes are obtained. The CP asymmetries in these decays are also determined. No significant CP violation is observed
The Cabibbo-allowed weak radiative decay Λ+c→Σ+γ has been searched for in a sample of Λ+cΛ¯−c pairs produced in e+e− annihilations, corresponding to an integrated luminosity of 4.5fb−1 collected with the BESIII detector at center-of-mass energies between 4.60 and 4.70 GeV. No excess of signal above background is observed, and we set an upper limit on the branching fraction of this decay to be B(Λ+c→Σ+γ)<4.4×10−4 at a confidence level of 90\%, which is in agreement with Standard Model expectations.
Improved measurement of the branching fractions of the inclusive decays D⁺ → Kₛ⁰X and D⁰ → Kₛ⁰X
(2023)
By analyzing 2.93 fb−1 of 𝑒+𝑒− collision data taken at the center-of-mass energy of 3.773 GeV with the BESIII detector, the branching fractions of the inclusive decays 𝐷+→𝐾0 𝑆𝑋 and 𝐷0→𝐾0 𝑆𝑋 are measured to be (33.11±0.13±0.36)% and (20.75±0.12±0.20)%, respectively, where the first uncertainties are statistical and the second are systematic. These results are consistent with the world averages of previous measurements, but with much improved precision.
Using 7.33 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.128 and 4.226~GeV, we observe for the first time the decay D±s→ωπ±η with a statistical significance of 7.6σ. The measured branching fraction of this decay is (0.54±0.12±0.04)%, where the first uncertainty is statistical and the second is systematic.
Observation of resonance structures in e⁺e⁻ → π⁺π⁻ψ₂(3823) and mass measurement of ψ₂(3823)
(2022)
Using a data sample corresponding to an integrated luminosity of 11.3 fb−1 collected at center-of-mass energies from 4.23 to 4.70 GeV with the BESIII detector, we measure the product of the 𝑒+𝑒−→𝜋+𝜋−𝜓2(3823) cross section and the branching fraction ℬ[𝜓2(3823)→𝛾𝜒𝑐1]. For the first time, resonance structure is observed in the cross section line shape of 𝑒+𝑒−→𝜋+𝜋−𝜓2(3823) with significances exceeding 5𝜎. A fit to data with two coherent Breit-Wigner resonances modeling the √𝑠-dependent cross section yields 𝑀(𝑅1)=4406.9±17.2±4.5 MeV/𝑐2, Γ(𝑅1)=128.1±37.2±2.3 MeV, and 𝑀(𝑅2)=4647.9±8.6±0.8 MeV/𝑐2, Γ(𝑅2)=33.1±18.6±4.1 MeV. Though weakly disfavored by the data, a single resonance with 𝑀(𝑅)=4417.5±26.2±3.5 MeV/𝑐2, Γ(𝑅)=245±48±13 MeV is also possible to interpret data. This observation deepens our understanding of the nature of the vector charmoniumlike states. The mass of the 𝜓2(3823) state is measured as (3823.12±0.43±0.13) MeV/𝑐2, which is the most precise measurement to date.
The integrated luminosities of data samples collected in the BESIII experiment in 2016–2017 at center-of-mass energies between 4.19 and 4.28 GeV are measured with a precision better than 1% by analyzing large-angle Bhabha scattering events. The integrated luminosities of old datasets collected in 2010–2014 are updated by considering corrections related to detector performance, offsetting the effect of newly discovered readout errors in the electromagnetic calorimeter, which can haphazardly occur.
Using data samples collected with the BESIII detector operating at the BEPCII storage ring, the cross section of the inclusive process e+e−→η+X, normalized by the total cross section of e+e−→hadrons, is measured at eight center-of-mass energy points from 2.0000 GeV to 3.6710 GeV. These are the first measurements with momentum dependence in this energy region. Our measurement shows a significant discrepancy from calculations with the existing fragmentation functions. To address this discrepancy, a new QCD analysis is performed at the next-to-next-to-leading order with hadron mass corrections and higher twist effects, which can explain both the established high-energy data and our measurements reasonably well.
Based on electron positron collision data collected with the BESIII detector operating at the BEPCII storage rings, the differential cross sections of inclusive π0 and K0S production as a function of hadron momentum, normalized by the total cross section of the e+e−→ hadrons process, are measured at six center-of-mass energies from 2.2324 to 3.6710 GeV. Our results with a relative hadron energy coverage from 0.1 to 0.9 significantly deviate from several theoretical calculations based on existing fragmentation functions, especially at lower energies.
Based on electron positron collision data collected with the BESIII detector operating at the BEPCII storage rings, the differential cross sections of inclusive π0 and K0S production as a function of hadron momentum, normalized by the total cross section of the e+e−→ hadrons process, are measured at six center-of-mass energies from 2.2324 to 3.6710 GeV. Our results with a relative hadron energy coverage from 0.1 to 0.9 significantly deviate from several theoretical calculations based on existing fragmentation functions, especially at lower energies.
The decay 𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂 is searched for through the radiative transition 𝜓(3686)→𝛾𝜂𝑐(2𝑆) using 448 million 𝜓(3686) events accumulated at the BESIII detector. The first evidence of 𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂 is found with a statistical significance of 3.5𝜎. The product of the branching fractions of 𝜓(3686)→𝛾𝜂𝑐(2𝑆) and 𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂 is measured to be Br(𝜓(3686)→𝛾𝜂𝑐(2𝑆))×Br(𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂)=(2.97±0.81±0.26)×10−6, where the first uncertainty is statistical and the second one is systematic. The branching fraction of the decay 𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂 is determined to be Br(𝜂𝑐(2𝑆)→𝜋+𝜋−𝜂)=(42.4±11.6±3.8±30.3)×10−4, where the third uncertainty is transferred from the uncertainty of the branching fraction of 𝜓(3686)→𝛾𝜂𝑐(2𝑆).
The decay $\eta_c(2S)\to\pipieta$ is searched for through the radiative transition ψ(3686)→γηc(2S) using 448 million ψ(3686) events accumulated at the BESIII detector. The first evidence of ηc(2S)→π+π−η is found with a statistical significance of 3.5σ. The product of the branching fractions of ψ(3686)→γηc(2S) and $\eta_c(2S)\to\pipieta$ is measured to be $Br(\psi(3686)\to\gamma\eta_c(2S))\times Br(\eta_c(2S)\to\pipieta)=(2.97\pm0.81\pm0.26)\times10^{-6}$, where the first uncertainty is statistical and the second one is systematic. The branching fraction of the decay $\eta_c(2S)\to\pipieta$ is determined to be $Br(\eta_c(2S)\to\pipieta)=(42.4\pm11.6\pm3.8\pm30.3)\times10^{-4}$, where the third uncertainty is transferred from the uncertainty of the branching fraction of ψ(3686)→γηc(2S).
The decay $\eta_c(2S)\to\pipieta$ is searched for through the radiative transition ψ(3686)→γηc(2S) using 448 million ψ(3686) events accumulated at the BESIII detector. The first evidence of ηc(2S)→π+π−η is found with a statistical significance of 3.5σ. The product of the branching fractions of ψ(3686)→γηc(2S) and $\eta_c(2S)\to\pipieta$ is measured to be $Br(\psi(3686)\to\gamma\eta_c(2S))\times Br(\eta_c(2S)\to\pipieta)=(2.97\pm0.81\pm0.26)\times10^{-6}$, where the first uncertainty is statistical and the second one is systematic. The branching fraction of the decay $\eta_c(2S)\to\pipieta$ is determined to be $Br(\eta_c(2S)\to\pipieta)=(42.4\pm11.6\pm3.8\pm30.3)\times10^{-4}$, where the third uncertainty is transferred from the uncertainty of the branching fraction of ψ(3686)→γηc(2S).
We report a search for a heavier partner of the recently observed Zcs(3985)− state, denoted as Z′−cs, in the process e+e−→K+D∗−sD∗0+c.c., based on e+e− collision data collected at the center-of-mass energies of s√=4.661, 4.682 and 4.699 GeV with the BESIII detector. The Z′−cs is of interest as it is expected to be a candidate for a hidden-charm and open-strange tetraquark. A partial-reconstruction technique is used to isolate K+ recoil-mass spectra, which are probed for a potential contribution from Z′−cs→D∗−sD∗0 (c.c.). We find an excess of Z′−cs→D∗−sD∗0 (c.c.) candidates with a significance of 2.9σ, after considering systematic uncertainties, at a mass of (4123.5±0.7stat.±1.1syst.)MeV/c2. As the data set is limited in size, the upper limits are evaluated at the 90% confidence level on the product of the Born cross section and the branching fraction of Z′−cs→D∗−sD∗0, σBorn⋅B at the three energy points, under different assumptions of the Z′−cs mass from 4.120 to 4.140 MeV and of the width from 10 to 50 MeV. Under various mass and width assumptions, the upper limits of σBorn⋅B are found to lie in the range of 2∼6, 3∼7 and 3∼6 pb at s√=4.661, 4.682 and 4.699 GeV, respectively. The larger data samples that will be collected in the coming years will allow a clearer picture to emerge concerning the existence and nature of the Z′−cs state.
We report a measurement of the cross section for the process e+e−→π+π−J/ψ around the X(3872) mass in search for the direct formation of e+e−→X(3872) through the two-photon fusion process. No enhancement of the cross section is observed at the X(3872) peak and an upper limit on the product of electronic width and branching fraction of X(3872)→π+π−J/ψ is determined to be Γee×B(X(3872)→π+π−J/ψ)<7.5×10−3eV at 90% confidence level under an assumption of total width of 1.19±0.21 MeV. This is an improvement of a factor of about 17 compared to the previous limit. Furthermore, using the latest result of B(X(3872)→π+π−J/ψ), an upper limit on the electronic width Γee of X(3872) is obtained to be <0.32eV at the 90% confidence level.
Based on a sample of (10.09±0.04)×109 J/ψ events collected with the BESIII detector operating at the BEPCII storage ring, a partial wave analysis of the decay J/ψ→γηη′ is performed. An isoscalar state with exotic quantum numbers JPC=1−+, denoted as η1(1855), has been observed for the first time with statistical significance larger than 19σ. Its mass and width are measured to be (1855±9+6−1)~MeV/c2 and (188±18+3−8)~MeV, respectively. The product branching fraction B(J/ψ→γη1(1855)→γηη′) is measured to be (2.70±0.41+0.16−0.35)×10−6. The first uncertainties are statistical and the second are systematic. In addition, an upper limit on the branching ratio B(f0(1710)→ηη′)/B(f0(1710)→ππ) is determined to be 1.61×10−3 at 90\% confidence level, which lends support to the hypothesis that the f0(1710) has a large glueball component.
Study of ψ(3686) → ΛΛ¯ω
(2022)
Based on a data sample of (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector at the BEPCII collider, the branching fraction of ψ(3686)→ΛΛ¯ω is measured to be (3.30±0.34(stat.)±0.29(syst.))×10−5 for the first time. In addition, the Λω (or Λ¯ω) invariant mass spectra is studied and the potential presence of excited Λ states has been investigated.
We report a search for a heavier partner of the recently observed Zcs(3985)− state, denoted as Z′−cs, in the process e+e−→K+D∗−sD∗0+c.c., based on e+e− collision data collected at the center-of-mass energies of s√=4.661, 4.682 and 4.699 GeV with the BESIII detector. The Z′−cs is of interest as it is expected to be a candidate for a hidden-charm and open-strange tetraquark. A partial-reconstruction technique is used to isolate K+ recoil-mass spectra, which are probed for a potential contribution from Z′−cs→D∗−sD∗0 (c.c.). We find an excess of Z′−cs→D∗−sD∗0 (c.c.) candidates with a significance of 2.1σ, after considering systematic uncertainties, at a mass of (4123.5±0.7stat.±4.7syst.) MeV/c2. As the data set is limited in size, the upper limits are evaluated at the 90\% confidence level on the product of the Born cross sections (σBorn) and the branching fraction (B) of Z′−cs→D∗−sD∗0, under different assumptions of the Z′−cs mass from 4.120 to 4.140 MeV and of the width from 10 to 50 MeV at the three center-of-mass energies. The upper limits of σBorn⋅B are found to be at the level of O(1) pb at each energy. Larger data samples are needed to confirm the Z′−cs state and clarify its nature in the coming years.
We report a search for a heavier partner of the recently observed Zcs(3985)− state, denoted as Z′−cs, in the process e+e−→K+D∗−sD∗0+c.c., based on e+e− collision data collected at the center-of-mass energies of s√=4.661, 4.682 and 4.699 GeV with the BESIII detector. The Z′−cs is of interest as it is expected to be a candidate for a hidden-charm and open-strange tetraquark. A partial-reconstruction technique is used to isolate K+ recoil-mass spectra, which are probed for a potential contribution from Z′−cs→D∗−sD∗0 (c.c.). We find an excess of Z′−cs→D∗−sD∗0 (c.c.) candidates with a significance of 2.1σ, after considering systematic uncertainties, at a mass of (4123.5±0.7stat.±4.7syst.) MeV/c2. As the data set is limited in size, the upper limits are evaluated at the 90\% confidence level on the product of the Born cross sections (σBorn) and the branching fraction (B) of Z′−cs→D∗−sD∗0, under different assumptions of the Z′−cs mass from 4.120 to 4.140 MeV and of the width from 10 to 50 MeV at the three center-of-mass energies. The upper limits of σBorn⋅B are found to be at the level of O(1) pb at each energy. Larger data samples are needed to confirm the Z′−cs state and clarify its nature in the coming years.
Using data samples with an integrated luminosity of 19 fb−1 at twenty-eight center-of-mass energies from 3.872 GeV to 4.700 GeV collected with the BESIII detector at the BEPCII electron-positron collider, the process e+e− → ηπ+π− and the intermediate process e+e− → ηρ0 are studied for the first time. The Born cross sections are measured. No significant resonance structure is observed in the cross section lineshape.
Based on (10087±44)×106 J/ψ events collected with the BESIII detector, the process J/ψ→γπ+π−η′ is studied using two dominant decay channels of the η′ meson, η′→γπ+π− and η′→ηπ+π−,η→γγ. The X(2600) is observed with a statistical significance larger than 20σ in the π+π−η′ invariant mass spectrum, and it has a strong correlation to a structure around 1.5 GeV/{\it c}2 in the π+π− invariant mass spectrum. A simultaneous fit on the π+π−η′ and π+π− invariant mass spectra with the two η′ decay modes indicates that the mass and width of the X(2600) state are 2617.8±2.1+18.2−1.9 MeV/{\it c}2 and 200±8+20−17 MeV, respectively. The corresponding branching fractions are measured to be B(J/ψ→γX(2600))⋅B(X(2600)→f0(1500)η′)⋅B(f0(1500)→π+π−) = (3.39±0.18+0.91−0.66)×10−5 and B(J/ψ→γX(2600))⋅B(X(2600)→f′2(1525)η′)⋅B(f′2(1525)→π+π−) = (2.43±0.13+0.31−1.11)×10−5, where the first uncertainties are statistical, and the second systematic.
Using data samples with an integrated luminosity of 6.4~fb−1 collected by the BESIII detector operating at the BEPCII storage ring, the process of e+e−→γϕJ/ψ is studied. The processes of e+e−→ϕχc1,c2, χc1,c2→γJ/ψ are observed with a significance of more than 10σ. The s√-dependent cross section of e+e−→ϕχc1,c2 is measured between 4.600 and 4.951~GeV, and evidence of a resonance structure is found for the first time in the ϕχc2 process. We also search for the processes of e+e−→γX(4140), γX(4274) and γX(4500) via the γϕJ/ψ final state, but no obvious structures are found. The upper limits on the production cross section times the branching fraction for these processes at the 90% confidence level are reported.
Using electron-positron annihilation data samples corresponding to an integrated luminosity of 4.5 fb−1, collected by the BESIII detector in the energy region between 4600 MeV and 4699 MeV, we report the first observations of the Cabibbo-suppressed decays Λ+c→nπ+π0, Λ+c→nπ+π−π+, and the Cabibbo-favored decay Λ+c→nK−π+π+ with statistical significances of 7.9σ, 7.8σ, and >10σ, respectively. The branching fractions of these decays are measured to be B(Λ+c→nπ+π0)=(0.64±0.09±0.02)%, B(Λ+c→nπ+π−π+)=(0.45±0.07±0.03)%, and B(Λ+c→nK−π+π+)=(1.90±0.08±0.09)%, where the first uncertainties are statistical and the second are systematic. We find that the branching fraction of the decay Λ+c→nπ+π0 is about one order of magnitude higher than that of Λ+c→nπ+.
Using a data sample corresponding to an integrated luminosity of 11.3 fb−1 collected at center-of-mass energies from 4.23 to 4.70 GeV with the BESIII detector, we observe the process e+e− → π0π0ψ2(3823) for the first time with a statistical significance of 6.0 standard deviations. The ratio of average cross sections for e+e− → π0π0ψ2(3823) and π+π−ψ2(3823) is determined to be R = σ[e+e− → π0π0ψ2(3823)] σ[e+e−→π+π−ψ2(3823)] = 0.57 ± 0.14 ± 0.05, which is consistent with expectations from isospin symmetry. Here and below, the first uncertainties are statistical and the second are systematic. The mass of the ψ2(3823) is measured to be M[ψ2(3823)] = 3824.5±2.4±1.0 MeV/c2. Due to the limited data sample, an upper limit of 18.8 MeV at 90% confidence level is set on the intrinsic width of ψ2(3823).
Using (448.1 ± 2.9) × 106 ψ(3686) events collected with the BESIII detector at the BEPCII collider, the decay ψ(3686) → Σ⁻Σ‾⁺ is observed for the first time with a branching fraction of (2.82 ± 0.04stat. ± 0.08syst.) × 10−4, and the angular parameter αΣ− is measured to be 0.96 ± 0.09stat. ± 0.03syst..
Based on electron-positron collision data collected with the BESIII detector operating at the BEPCII storage rings, the value of R≡σ(e+e−→hadrons)/σ(e+e−→μ+μ−) is measured at 14 center-of-mass energies from 2.2324 to 3.6710 GeV. The resulting uncertainties are less than 3.0%, and are dominated by systematic uncertainties.
Based on electron-positron collision data collected with the BESIII detector operating at the Beijing Electron Positron Collider II storage rings, the value of R≡σ(e+e−→hadrons)/σ(e+e−→μ+μ−) is measured at 14 center-of-mass energies from 2.2324 to 3.6710 GeV. The resulting uncertainties are less than 3.0%, and are dominated by systematic uncertainties.
Using a data sample of (1.0087±0.0044)×1010 J/ψ decay events collected with the BESIII detector at the center-of-mass energy of s√=3.097 GeV, we present a search for the hyperon semileptonic decay Ξ0→Σ−e+νe which violates the ΔS=ΔQ rule. No significant signal is observed, and the upper limit on the branching fraction B(Ξ0→Σ−e+νe) is determined to be 1.6×10−4 at the 90% confidence level. This result improves the previous upper limit result by about one order of magnitude.
Using a data sample of (1.0087±0.0044)×1010 J/ψ decay events collected with the BESIII detector at the center-of-mass energy of s√=3.097 GeV, we present a search for the hyperon semileptonic decay Ξ0→Σ−e+νe which violates the ΔS=ΔQ rule. No significant signal is observed, and the upper limit on the branching fraction B(Ξ0→Σ−e+νe) is determined to be 1.6×10−4 at the 90% confidence level. This result improves the previous upper limit result by about one order of magnitude.
A search for a massless dark photon 𝛾′ is conducted using 4.5 fb−1 of 𝑒+𝑒− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. No significant signal is observed, and the upper limit on the branching fraction ℬ(Λ+𝑐→𝑝𝛾′) is determined to be 8.0×10−5 at 90% confidence level.
A search for a massless dark photon γ′ is conducted using 4.5 fb−1 of e+e− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. No significant signal is observed, and the upper limit on the branching fraction B(Λ+c→pγ′) is determined to be 8.0×10−5 at 90% confidence level.
A search for a massless dark photon γ′ is conducted using 4.5 fb−1 of e+e− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. No significant signal is observed, and the upper limit on the branching fraction B(Λ+c→pγ′) is determined to be 8.0×10−5 at 90% confidence level.
Measurement of the absolute branching fraction of the singly Cabibbo suppressed decay Λc⁺ → pη′
(2022)
The singly Cabibbo suppressed decay Λ+𝑐→𝑝𝜂′ is measured using 4.5 fb−1 of 𝑒+𝑒− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. Evidence for Λ+𝑐→𝑝𝜂′ with a statistical significance of 3.6𝜎 is reported with a double-tag approach. The Λ+𝑐→𝑝𝜂′ absolute branching fraction is determined to be (5.62+2.46−2.04±0.26)×10−4, where the first and second uncertainties are statistical and systematic, respectively. Our result is consistent with the branching fraction obtained by the Belle collaboration within the uncertainty of 1𝜎.
Measurement of the absolute branching fraction of the singly Cabibbo suppressed decay Λc⁺ → pη′
(2022)
The singly Cabibbo suppressed decay Λ+c→pη′ is measured using 4.5 fb−1 of e+e− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. Evidence for Λ+c→pη′ with a statistical significance of 3.6σ is reported with a double-tag approach. The Λ+c→pη′ absolute branching fraction is determined to be (5.62+2.46−2.04±0.26)×10−4, where the first and second uncertainties are statistical and systematic, respectively. Our result is consistent with the branching fraction obtained by the Belle collaboration within the uncertainty of 1σ.
Measurement of the absolute branching fraction of the singly Cabibbo suppressed decay Λc⁺ → pη′
(2022)
The singly Cabibbo suppressed decay Λ+c→pη′ is measured using 4.5 fb−1 of e+e− collision data collected at center-of-mass energies between 4.600 and 4.699 GeV with the BESIII detector at BEPCII. Evidence for Λ+c→pη′ with a statistical significance of 3.6σ is reported with a double-tag approach. The Λ+c→pη′ absolute branching fraction is determined to be (5.62+2.46−2.04±0.26)×10−4, where the first and second uncertainties are statistical and systematic, respectively. Our result is consistent with the branching fraction obtained by the Belle collaboration within the uncertainty of 1σ.
The study of the Cabibbo-favored semileptonic decay Λ+𝑐→Λ𝑒+𝜈𝑒 is reported using a 4.5 fb−1 data sample of 𝑒+𝑒− annihilations collected at center-of-mass energies ranging from 4.600 GeV to 4.699 GeV with the BESIII detector at the BEPCII collider. The branching fraction of the decay is measured to be ℬ(Λ+𝑐→Λ𝑒+𝜈𝑒)=(3.56±0.11stat±0.07syst)%, which is the most precise measurement to date. Furthermore, we perform an investigation of the internal dynamics in Λ+𝑐→Λ𝑒+𝜈𝑒. We provide the first direct comparisons of the differential decay rate and form factors with those predicted from lattice quantum chromodynamics (LQCD) calculations. Combining the measured branching fraction with a 𝑞2-integrated rate predicted by LQCD, we determine 𝑉𝑐𝑠|=0.936±0.017ℬ±0.024LQCD±0.007𝜏Λ𝑐.
Using 4.5 fb−1 of e+e− annihilation data samples collected at the center-of-mass energies ranging from 4.600~GeV to 4.699~GeV with the BESIII detector at the BEPCII collider, a first study of the semileptonic decays Λ+c→pK−e+νe, Λ+c→Λ(1520)e+νe and Λ+c→Λ(1405)e+νe is performed. The Λ+c→pK−e+νe decay is observed with a significance of 8.2σ and the branching fraction is measured to be B(Λ+c→pK−e+νe)=(0.88±0.17stat.±0.07syst.)×10−3. We also report evidence of Λ+c→Λ(1520)e+νe and Λ+c→Λ(1405)e+νe with significances of 3.3σ and 3.2σ, respectively, and measure B(Λ+c→Λ(1520)e+νe)=(1.02±0.52stat.±0.11syst.)×10−3 and B(Λ+c→Λ(1405)[→pK−]e+νe)=(0.42±0.19stat.±0.04syst.)×10−3. Combining these with the inclusive semileptonic Λ+c branching fraction measured by BESIII, the relative fraction is determined to be [B(Λ+c→pK−e+νe)/B(Λ+c→Xe+νe)]=(2.1±0.4stat.±0.2syst.)%, which provides a clear confirmation that semileptonic Λ+c decays are not saturated by the Λℓ+νℓ final state.
Based on a sample of 4.4 fb−1 of e+e− annihilation data collected in the energy region between 4.6 GeV and 4.7 GeV with the BESIII detector at BEPCII, two singly Cabibbo-suppressed decays Λ+c→Σ0K+ and Λ+c→Σ+K0S are studied. The ratio of the branching fraction B(Λ+c→Σ0K+) relative to B(Λ+c→Σ0π+) is measured to be 0.0361±0.0073(stat.)±0.0005(syst.), and the ratio of B(Λ+c→Σ+K0S) relative to B(Λ+c→Σ+π+π−) is measured to be 0.0106±0.0031(stat.)±0.0004(syst.). After taking the world-average branching fractions of the reference decay channels, the branching fractions B(Λ+c→Σ0K+) and B(Λ+c→Σ+K0S) are determined to be (4.7±0.9(stat.)±0.1(syst.)±0.3(ref.))×10−4 and (4.8±1.4(stat.)±0.2(syst.)±0.3(ref.))×10−4, respectively. The branching fraction of the Λ+c→Σ+K0S decay is measured for the first time.
Using (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector, we perform the first search for the weak baryonic decay ψ(3686)→Λ+cΣ¯−+c.c.. The analysis procedure is optimized using a blinded method. No significant signal is observed, and the upper limit on the branching fraction (B) of ψ(3686)→Λ+cΣ¯−+c.c. is set to be 1.4×10−5 at the 90\% confidence level.
Using (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector, we perform the first search for the weak baryonic decay ψ(3686)→Λ+cΣ¯−+c.c.. The analysis procedure is optimized using a blinded method. No significant signal is observed, and the upper limit on the branching fraction (B) of ψ(3686)→Λ+cΣ¯−+c.c. is set to be 1.4×10−5 at the 90\% confidence level.